| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MFN1 |
| Uniprot No | Q8IWA4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-741aa |
| 氨基酸序列 | MAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIAT EDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKV LPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDK DLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDAD VFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYME DVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMP ESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILAT VKNIMDSVNLAAEDKRHYSVEEREDQIDRLDFIRNQMNLLTLDVKKKIKE VTEEVANKVSCAMTDEICRLSVLVDEFCSEFHPNPDVLKIYKSELNKHIE DGMGRNLADRCTDEVNALVLQTQQEIIENLKPLLPAGIQDKLHTLIPCKK FDLSYNLNYHKLCSDFQEDIVFRFSLGWSSLVHRFLGPRNAQRVLLGLSE PIFQLPRSLASTPTAPTTPATPDNASQEELMITLVTGLASVTSRTSMGII IVGGVIWKTIGWKLLSVSLTMYGALYLYERLSWTTHAKERAFKQQFVNYA TEKLRMIVSSTSANCSHQVKQQIATTFARLCQQVDITQKQLEEEIARLPK EIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES |
| 预测分子量 | 107 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MFN1重组蛋白的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **"Reconstitution of Mitofusin-Dependent Mitochondrial Fusion in Vitro"**
*Authors: Rui Ji, Yifan Ge, Wenjing Li, et al.*
**摘要**：该研究利用重组MFN1蛋白在体外重建了线粒体膜融合过程，证实其GTP酶活性对融合至关重要，并揭示了其与脂质膜的相互作用机制。
2. **"Structural Basis of Mitochondrial Tethering by Mitofusin Complexes"**
*Authors: Shuxia Yan, Xin Qi, Xiaochen Li, et al.*
**摘要**：通过冷冻电镜解析重组MFN1蛋白的寡聚结构，提出MFN1通过形成反式复合体介导线粒体膜栓系的分子模型。
3. **"Functional Characterization of MFN1 Variants Associated with Neurodegeneration"**
*Authors: Laura L. Perera, Michael A. Forte, et al.*
**摘要**：表达并纯化疾病相关的MFN1突变体重组蛋白，发现其导致GTP酶活性丧失及线粒体碎片化，提示功能缺陷与神经退行性疾病相关。
---
注：以上文献为示例性质，实际引用时建议通过学术数据库(如PubMed、Web of Science)核对最新研究。如需具体文献，可进一步提供检索指导。
**Background of MFN1 Recombinant Protein**
Mitofusin 1 (MFN1) is a mitochondrial outer membrane protein critical for regulating mitochondrial dynamics, particularly fusion. It belongs to the dynamin-related GTPase family and plays a key role in maintaining mitochondrial morphology, bioenergetic function, and cellular homeostasis. MFN1 mediates the tethering and fusion of adjacent mitochondria by interacting with its homolog MFN2. ensuring proper distribution of mitochondrial DNA, metabolites, and proteins. Dysregulation of MFN1 is linked to neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), metabolic disorders, and Charcot-Marie-Tooth disease type 2A.
Recombinant MFN1 protein is produced using heterologous expression systems, such as *E. coli* or mammalian cell lines, to enable large-scale study of its structure and function. The recombinant form typically includes tags (e.g., His-tag, GST) for purification and detection. Its production allows researchers to investigate MFN1’s GTPase activity, oligomerization properties, and interactions with partners like MFN2 or apoptosis-inducing factors.
Structurally, MFN1 contains a GTPase domain, helical bundle regions, and transmembrane domains essential for membrane anchoring. Recombinant variants may exclude transmembrane regions for solubility or include mutations to study disease-related dysfunction. Applications span *in vitro* assays (e.g., mitochondrial fusion reconstitution), drug screening for mitochondrial disorders, and structural studies via cryo-EM or X-ray crystallography.
Challenges in producing functional MFN1 recombinant protein include preserving post-translational modifications and membrane-associated conformations. Advances in expression systems and purification techniques continue to enhance its utility in understanding mitochondrial biology and therapeutic development.
×
